Monopar Therapeutics Inc. Announces $19.2 Million Public Stock Offering

Monopar Therapeutics Inc. has announced the pricing of its public offering of common stock, set at $16.25 per share, resulting in approximately $19.2 million in gross proceeds. This figure is noted before the deduction of placement agent fees and other related expenses. The company, listed on Nasdaq under the ticker MNPR, expects the offering to close by October 30, 2024, pending standard closing conditions.

The offering saw participation from notable investors, including Janus Henderson Investors and RA Capital Management, L.P., along with other prominent growth and life science investors. Rodman & Renshaw LLC is serving as the exclusive placement agent for this transaction.

Monopar Therapeutics plans to utilize the net proceeds from the stock offering for various general corporate purposes. These include funding research and development projects, covering clinical trial costs, manufacturing and supplying products, and supporting working capital needs.

The securities are being sold under a "shelf" registration statement on Form S-3, filed with the U.S. Securities and Exchange Commission (SEC) on December 21, 2022, and declared effective on January 4, 2023. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and is accessible on their website. The final terms will be detailed in a subsequent prospectus supplement.

This announcement is not a sales offer or a solicitation to purchase the securities described. Sales will only be conducted in accordance with state or jurisdictional securities laws. Offers will be made through the prospectus supplement and accompanying prospectus forming part of the effective registration statement.

Monopar Therapeutics is a clinical-stage biotechnology firm concentrating on developing new treatments for patients with unmet medical needs. The company's portfolio includes the late-stage ALXN-1840 for Wilson disease and various radiopharma programs, such as the Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1a-stage MNPR-101-Lu, and late preclinical-stage MNPR-101-Ac225, both aimed at treating advanced cancers.